FIELD: biotechnology.
SUBSTANCE: invention relates specifically to the production of interleukin 15 (IL-15) conjugates and can be used in medicine for the treatment of cancer. Modified IL-15 polypeptides conjugated to a water-soluble polymer with a molecular weight of 20 kDa - 85 kDa are proposed. Moreover, the specified polymer is attached to the IL-15 polypeptide through an unnatural amino acid with an azido group at a position selected from L25, N77, V49 and S83 according to SEQ ID NO: 1.
EFFECT: invention provides for the production of IL-15 conjugates with an increased half-life compared to the half-life of the wild-type IL-15 protein and with reduced binding toα interleukin 15 receptor (IL-15Rα), but retaining a significant degree of binding to the signaling complexβγ interleukin 15 receptor (IL-15Rβγ ) to form the IL-15/IL-15R complexβγ , where the degree of binding to IL-15Rα is reduced compared to binding between wild-type IL-15 polypeptide and IL-15Rα.
46 cl, 17 dwg, 15 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CYTOKINE CONJUGATES FOR TREATMENT OF AUTOIMMUNE DISEASES | 2018 |
|
RU2787201C2 |
| CYTOKINE CONJUGATES FOR TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | 2018 |
|
RU2786116C2 |
| INTERLEUKIN 10 CONJUGATES AND OPTIONS FOR THEIR USE | 2019 |
|
RU2815891C2 |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-R[ALPHA] SUSHI DOMAIN | 2012 |
|
RU2644671C2 |
| METHOD FOR PURIFYING CONJUGATES BASED ON IL-15/IL-15Rα | 2015 |
|
RU2701301C2 |
| SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION BY MEANS OF GLYCOENGINEERING | 2014 |
|
RU2711935C2 |
| HYPERGLYCOSYLATED BINDING POLYPEPTIDES | 2014 |
|
RU2708314C2 |
| PHARMACEUTICAL STRUCTURES WITH INCREASED ALBUMIN BINDING AFFINITY | 2018 |
|
RU2753880C1 |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-15Rα OF THE SUSHI DOMAIN | 2012 |
|
RU2763298C2 |
| CONJUGATE OF ANTIBODY AND DRUG, COMPOSITIONS BASED ON SAID CONJUGATE AND METHODS OF PRODUCING SAID CONJUGATE | 2015 |
|
RU2728235C2 |
